Clinical Trials · NCT06184568
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 349
- Start date
- Feb 2024
- Locations
- 1 site, China
- Primary endpoint
- Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss